ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback